BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27732951)

  • 1. IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.
    Rinkenbaugh AL; Cogswell PC; Calamini B; Dunn DE; Persson AI; Weiss WA; Lo DC; Baldwin AS
    Oncotarget; 2016 Oct; 7(43):69173-69187. PubMed ID: 27732951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.
    Garner JM; Fan M; Yang CH; Du Z; Sims M; Davidoff AM; Pfeffer LM
    J Biol Chem; 2013 Sep; 288(36):26167-26176. PubMed ID: 23902772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma.
    Wang H; Pan JQ; Luo L; Ning XJ; Ye ZP; Yu Z; Li WS
    Mol Cancer; 2015 Feb; 14():2. PubMed ID: 25971746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop.
    Tu Y; Xie P; Du X; Fan L; Bao Z; Sun G; Zhao P; Chao H; Li C; Zeng A; Pan M; Ji J
    J Cell Mol Med; 2019 Oct; 23(10):6907-6918. PubMed ID: 31430050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
    Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
    Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
    Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA
    Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy.
    Helweg LP; Storm J; Witte KE; Schulten W; Wrachtrup L; Janotte T; Kitke A; Greiner JFW; Knabbe C; Kaltschmidt B; Simon M; Kaltschmidt C
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.
    Ghosh D; Ulasov IV; Chen L; Harkins LE; Wallenborg K; Hothi P; Rostad S; Hood L; Cobbs CS
    Stem Cells; 2016 Sep; 34(9):2276-89. PubMed ID: 27354342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment.
    Nandhu MS; Kwiatkowska A; Bhaskaran V; Hayes J; Hu B; Viapiano MS
    Oncogene; 2017 Aug; 36(34):4875-4886. PubMed ID: 28414309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical NF-κB activation impairs skeletal muscle oxidative phenotype by reducing IKK-α expression.
    Remels AH; Gosker HR; Langen RC; Polkey M; Sliwinski P; Galdiz J; van den Borst B; Pansters NA; Schols AM
    Biochim Biophys Acta; 2014 Feb; 1842(2):175-85. PubMed ID: 24215713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A4 suppresses cancer stem cell proliferation via interaction with the IKK/NF-κB signaling pathway.
    Zhu Y; Zhou Y; Zhou X; Guo Y; Huang D; Zhang J; Wang C; Cai L
    BMC Cancer; 2018 Jul; 18(1):763. PubMed ID: 30045697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation.
    Zhang X; Chen T; Zhang J; Mao Q; Li S; Xiong W; Qiu Y; Xie Q; Ge J
    Cancer Sci; 2012 Feb; 103(2):181-90. PubMed ID: 22093097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NF-κB in glioblastoma: A therapeutic approach.
    Friedmann-Morvinski D; Narasimamurthy R; Xia Y; Myskiw C; Soda Y; Verma IM
    Sci Adv; 2016 Jan; 2(1):e1501292. PubMed ID: 26824076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
    Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
    Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF-κB Signaling Pathway.
    Ohtsu N; Nakatani Y; Yamashita D; Ohue S; Ohnishi T; Kondo T
    Cancer Res; 2016 Jan; 76(1):171-81. PubMed ID: 26677976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
    Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
    Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFIT5 positively regulates NF-κB signaling through synergizing the recruitment of IκB kinase (IKK) to TGF-β-activated kinase 1 (TAK1).
    Zheng C; Zheng Z; Zhang Z; Meng J; Liu Y; Ke X; Hu Q; Wang H
    Cell Signal; 2015 Dec; 27(12):2343-54. PubMed ID: 26334375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma.
    Kijewska M; Kocyk M; Kloss M; Stepniak K; Korwek Z; Polakowska R; Dabrowski M; Gieryng A; Wojtas B; Ciechomska IA; Kaminska B
    Oncotarget; 2017 Mar; 8(10):16340-16355. PubMed ID: 28030801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.
    Drube S; Weber F; Göpfert C; Loschinski R; Rothe M; Boelke F; Diamanti MA; Löhn T; Ruth J; Schütz D; Häfner N; Greten FR; Stumm R; Hartmann K; Krämer OH; Dudeck A; Kamradt T
    Oncotarget; 2015 Oct; 6(30):28833-50. PubMed ID: 26353931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.